Lupin
Working at Lupin
Company Summary
Overall Rating
8% above
Highly rated for
Company culture, Skill development, Work-life balance
Work Policy
Top Employees Benefits
About Lupin
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
AmbitionBox Best Places to Work in India Awards
Pharma Company
Lupin Ratings
Overall Rating
Category Ratings
Company culture
Skill development
Work-life balance
Salary
Work satisfaction
Job security
Promotions
Work Policy at Lupin
Lupin Reviews
Top mentions in Lupin Reviews
Compare Lupin with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 4.2/5 based on 5.9k reviews | 4.0/5 based on 5.6k reviews | 4.1/5 based on 6.7k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Company culture Work-life balance | Salary Job security Skill development | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 86% employees reported | Work from office 84% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 347 women | 4.0 Good rated by 416 women | 4.1 Good rated by 649 women | - no rating available |
Rating by Men Employees | 4.2 Good rated by 5.2k men | 4.0 Good rated by 4.9k men | 4.1 Good rated by 5.6k men | - no rating available |
Job security | 3.7 Good | 3.9 Good | 3.7 Good | 4.0 Good |
Lupin Salaries
Officer
Research Associate
Production Officer
Junior Officer
Senior Officer
Medical Representative
Area Sales Manager
Executive Production
Marketing Executive
Quality Control Officer
Lupin Interview Questions
Interview questions by designation
Top Lupin interview questions and answers
Lupin Jobs
Lupin News
Stocks that will see action today: January 9, 2025
- PI Industries has received an Order from the Commissioner of Customs for a classification dispute, imposing a liability of ₹38.91 crore.
- Solex Energy Ltd has achieved a remarkable revenue growth of 103% in the current financial year, with consolidated revenue reaching ₹408 crore.
- Lupin has received the EIR from the US FDA for its Pithampur Unit-1 manufacturing facility.
- Reserve Bank has lifted business restrictions on Asirvad Micro Finance and DMI Finance, imposed due to supervisory concerns.
Stocks In News: JSW Energy To Lupin — Top Gainers And Losers
- JSW Energy Ltd. is named as Motilal Oswal's top pick in the power utility sector for 2025.
- Lupin Ltd. rose by 1.34% after announcing the acquisition of Huminsulin in India from Eli Lilly and Co.
- Mazagon Dock Shipbuilders Ltd. saw its share price recover after signing a contract worth Rs 1,990 crore.
- Easy Trip Planners Ltd., the parent company of EaseMyTrip, dropped 9.9% following a large equity trade.
Shares of Lupin Ltd reach all-time high price on acquiring Huminsulin from Eli Lilly
- Lupin Ltd. acquires Huminsulin range of products in India from Eli Lilly, strengthening its position in the Indian diabetes market.
- Huminsulin range helps regulate blood sugar levels in adults and children with type 1 and type 2 diabetes.
- Acquisition enables Lupin to offer a comprehensive range of human insulin options to patients in India.
- Analysts maintain a 'buy' rating on Lupin, expecting potential delay in generic drug launch to benefit the company.
Lupin Strengthens Diabetes Portfolio with Huminsulin Acquisition from Lilly
- Lupin Ltd has acquired the anti-diabetic medicine 'Huminsulin' in India from Eli Lilly and Company.
- The acquisition aims to strengthen Lupin's diabetes portfolio.
- Lupin has been marketing the 'Huminsulin' range through agreements with Lilly in India.
- This acquisition enables Lupin to offer a broad range of human insulin options to patients.
Lupin Shares Hit Life High Following Huminsulin Acquisition
- Shares of Lupin Ltd. surged by 1.34% after announcing the acquisition of Huminsulin in India from Eli Lilly and Co.
- The acquisition aims to enhance Lupin's diabetes portfolio and improve affordable healthcare access for patients in India.
- Huminsulin products are used for the treatment of type 1 and type 2 diabetes mellitus.
- Lupin's stock has risen 78.03% in the last 12 months.
Stocks To Watch Today: Lupin, Mazagon Dock, RVNL, Wipro, Unimech Aerospace
- Lupin Ltd., Rail Vikas Nigam Ltd., Mazagon Dock Shipbuilders Ltd. and Prestige Estates Projects Ltd. are some of the stocks in focus.
- Lupin announced the acquisition of Huminsulin in India from US drugmaker Eli Lilly.
- RVNL emerged as the lowest bidder for a central railway project worth Rs 137.16 crore.
- Mazagon Dock signed a contract worth Rs 1,990 crore with the Ministry of Defence for air independent propulsion plug.
Lupin To Acquire Huminsulin In India From Eli Lily To Augment Diabetes Portfolio
- Lupin Ltd. has acquired the Huminsulin range of products from Eli Lilly to strengthen its diabetes portfolio in India.
- The acquisition includes Insulin Human formulations, which are used for managing type 1 and type 2 diabetes mellitus.
- Lupin aims to provide affordable healthcare and comprehensive care for diabetes patients through this strategic move.
- The acquisition further strengthens Lupin's diabetes portfolio and allows them to offer a broad range of human insulin options.
Tech Query: What is the outlook for Axis Bank, ONGC, Lupin, IDFC First Bank?
- Axis Bank: The stock is in a corrective fall but has strong support levels at ₹1,060 and ₹1,000. Resuming uptrend expected with a target of ₹1,500.
- ONGC: Short-term outlook is bearish with resistance at ₹270-₹280. A fall to ₹210-₹190 is expected. Long-term rally possible from ₹200 with a target of ₹350.
- Lupin: The stock is in a strong uptrend with support at ₹1,950. Potential target of ₹2,700. Stop-loss at ₹1,880.
- IDFC First Bank: Strong downtrend with potential support at ₹59-₹58. No trend reversal in sight. Exit recommended.
Trading Ideas: Experts Prefer Anant Raj And Lupin In Their Respective Sectors; Advise To Cut JTL
- Market experts prefer Anant Raj Ltd. in the real estate space and Lupin Ltd. in the pharma sector.
- They advise reducing position or exposure to JTL Industries Ltd.
- Experts recommend waiting for clarity on Bharat Global Developers Ltd.'s suspension.
- Investors are advised to hold Sagility India Ltd. for the medium term in the US healthcare space.
Stock Market Live: GIFT Nifty Above 24,700; Bharat Forge, HG Infra, Lupin, Paytm Share Prices In Focus
- The GIFT Nifty was trading above 24,700 in early trade Monday.
- Stock prices of Bharat Forge Ltd., H.G. Infra Engineering Ltd., Lupin Ltd., and One 97 Communications Ltd. may react to news flow over the weekend.
- Live updates on the Indian stock market are available.
- Stay updated with stock market news on NDTV Profit.
Lupin Subsidiaries
Rubamin
Lupin Digital Health
Polynova Industries
Novel Laboratories Inc
Compare Lupin with
Contribute & help others!
Companies Similar to Lupin
Lupin FAQs
Reviews
Interviews
Salaries
Users/Month